Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1117570 for acute schizophrenia exacerbation in hospitalized adults
2025-521868-35-00Phase 2Authorised
- Sponsor
- Neurocrine Biosciences
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing NBI-1117570 with Placebo (2 arms). Primary endpoint: Change from baseline in PANSS total score. Planned start Apr 2026; status: authorised.
02
Drugs
NBI-1117570
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2025-521868-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521868-35-00.